ReviewLife (Basel, Switzerland)2025
Oropouche Virus: An Emerging Arboviral Threat and Its Implications for Europe.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unresolved questions in pediatric dengue: from disease mechanisms to prevention.Current opinion in infectious diseases · 2026Review
- Pediatric Arboviral Infections in Europe: Epidemiology, Clinical Features, Diagnosis and Prevention.Viruses · 2026Review
- Oropouche Virus: Comparative Study of Two Strains Reveals Distinct Innate Immunity Modulation.Viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropouche virus (OROV), an emerging arbovirus of the Peribunyaviridae family, is responsible for acute febrile illness and, in some cases, neurological or hemorrhagic complications. Although traditionally confined to tropical areas of Central and South America, the 2024-2025 epidemic has signaled a major shift in its geographic and clinical profile, with sustained transmission in the Caribbean, over 15,000 confirmed cases, and the first imported infections reported in Europe and the United States. New clinical observations include fatalities in previously healthy adults, suspected vertical transmission with adverse fetal outcomes, and potential sexual transmission. Despite entomological data indicating low competence of European mosquito species and the absence of the main vector
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.